Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy Birthday Margaret!
Flaskworks EDEN device.
I mean OS KM curves between 0 and 32,9 months from randomization. ( between 0 and 36 months from surgery)
I agree eagle8. Thanks.
Newly Diagnosed GBM: Significant Residual Disease Slide
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168826841
1 out of 163 ECA patients (Newly Diagnosed GBM: Significant Residual Disease) alive 36 months from randomization.
14 out of 86 DCVax-L patients (Newly Diagnosed GBM: Significant Residual Disease) alive 36 months from randomization.
That's what counts Ex.
Ex,
Newly Diagnosed GBM: Significant Residual Disease Slide
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168826841
86 dcvax-L patients and 163 ECA patients at risk. Do you believe there are patients with biopsies in that cohort of 163 ECA patients? (Newly Diagnosed GBM ECA : n=1366)
THE SOCIETY OF UNIVERSITY NEUROSURGEONS
Prague, Czech Republic
2022 ANNUAL MEETING
June 29th-July 3rd, 2022
Linda Liau:
"In conclusion, the addition of DCVax-L to SOC resulted in a clinically meaningful and statistically significant extension in overall survival for both nGBM and rGBM".
https://static1.squarespace.com/static/55d34232e4b0a3f1fd2a226a/t/62c6e8fdc8ae1c1cb61ae488/1657202946459/Website+SUN+2022.pdf
Thanks pgsd and ATLnsider.
Linda Liau and her husband Marvin Bergsneider in Praque. (July 2022)
https://universityofmiamineurosurgery.smugmug.com/SUN/Prague-2022/i-2hLmG4V/A
https://universityofmiamineurosurgery.smugmug.com/SUN/Prague-2022/i-QpFdhPm/A
Funny...
June 23, 2022
INSTAGRAM
Ashkan Keyoumars:
Thanks flipper44. Excellent!
Thanks sentiment! Great info!
Recent changes to NICE Methods and Processes have opened up a new route for market access.
Novocure is exploring the opportunity of a NICE technology appraisal for Optune.
Looks like the coffee break was great!
https://mobile.twitter.com/YorkshireBTC/status/1539981458433097730/photo/1
Linda Powers :7 th row.
Roger Stupp: 6 th row.
The end of another thoroughly intriguing day. Highlight had to be the #DCVax presentation. Very exciting. Now, time to get my ceilidh on! #BNOS2022 @BNOSofficial pic.twitter.com/gPIoNDYE3s
— Benjamin Sanderson (@Benji_Sanderson) June 23, 2022
Thanks!
#BNOS2022 if anyone can, Ash…Kan! Fantastic presentation of Prof Ashkan: exciting results from the Phase 3 trial of #DCVax-L in Glioblastoma @BNOSofficial @KingsNeuro pic.twitter.com/xDpZBYnZa1
— Pietro Ivo D'Urso MD FRCS (@pidurso) June 23, 2022
Prof Ashkan @KingsNeuro presenting promising results for DCVax for GBM with 2.8mo OS improvement, marked change in long term survival. Also slide showing predictors for good outocome. #bnos2022 pic.twitter.com/RPrO2sUV06
— Sally Price (@saspist) June 23, 2022
Oooooo, hello you. #BNOS2022 @NorthwestBio #braintumournorthwest pic.twitter.com/Hl1alIE0gl
— Benjamin Sanderson (@Benji_Sanderson) June 23, 2022
External controls to circumvent this problem. Elegant but I fear this will cast significant doubt and shadow over what may be a truly fantastic development in treatment of GBM. Feelings reminiscent of EF-14 trial. #BNOS2022 @BNOSofficial pic.twitter.com/KCHsUbA1zA
— Benjamin Sanderson (@Benji_Sanderson) June 23, 2022
#BNOS2022 Listening to The Prof talking about Autlogous Tumour Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma trial data @KingsNeuroLab @KingsNeuro @BrainTumourOrg https://t.co/1NOSwKGH3K pic.twitter.com/Y1cSbeuD3i
— HCEngagement (@EngagementHc) June 23, 2022
Prof Ashkan sharing the results of Phase 3 trial of DCVax in GBM #BNOS2022 @BNOSofficial pic.twitter.com/iyEh5aL12R
— Shaveta Mehta (@shaveta_mehta) June 23, 2022
2021 Advent Bioservices payment information for ADCV.
Cost for manufacturing 6 doses ( induction phase and booster phase) for 1 year of treatment: £150 000
Cost for ongoing (twice per year) maintenance doses: each semi-annual maintenance dose= £25.000
$NWBO looks like Advent is getting ready to ramp up production at Sawton pic.twitter.com/pqpjVZnVLr
— TiltMyBrain (@TiltMyBrain) April 16, 2021
The 2022 Rocky Mountain Neurosurgical Society Annual Meeting.
"The invited guests will be Linda Liau, Md, PhD"
2022 – 57th Annual Meeting – Coeur d’Alene,
June 18 – 22, 2022
https://rmns.org/2022-55th-annual-meeting-coeurdalene/
BetIsOn,
You can celebrate Linda Liau’s achievement on Friday, June 24.
You can attend in person or via Zoom. https://uclahs.az1.qualtrics.com/jfe/form/SV_74lrNbAPjHPowGG
Thanks Flipper44. You might be right. Your reasoning fits perfectly into my analysis of the trial. The missing MGMT data cannot come exclusively from the first 17 patients enrolled in the trial, IMO
The Danish Dude,
The “Innovative Medicines Fund” was announced almost a year ago. https://www.england.nhs.uk/2021/07/nhs-england-announces-new-innovative-medicines-fund-to-fast-track-promising-new-drugs/
It’s interesting to re-read Emeritus Professor of Neurosurgery Garth Cruickshank comments, IMO.
July 31, 2021
I asked him to clarify the censoring on the PFS curves and if he could tell us anything about the "smaller" unknown MGMT group. He forwarded the slide deck to me and told me it should contain the information I'm looking for. Smart guy!
Agreed. Unfortunately he wouldn't tell me the exact number.
Elvisdk,
I have no experience with Dr. Thomas Nesselhut's therapy.
I would ask him if a dendritic cell vaccine is made from your own tumor lysate. (as with DCVax-L). I doubt it.
His treatment seems similar to the therapy of Prof. Stefaan Van Gool at IOZK -Cologne - Germany.
This quote is from the website "Doing it for Laura":